Search

National societies

EHA pursues close collaboration with the national hematology societies to ensure that the professional hematology community in Europe is served in the best possible way.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Read more

Priority Points System

The Priority Points System is designed to recognize sponsors’ investment and continuous support for EHA activities, and are allocated for each sponsorship program and/or item.

Read more

Highlights of Past EHA (HOPE) Middle East and North Africa (MENA) 2021 - report

The sixth HOPE MENA, with highlights of the EHA Annual Congress, successfully concluded September 23-24. Fully virtual for the second year in a row, the program was compiled together with eight regional partner societies.

Read more

Is CRTH for me?

Eligibility
Applicant must be a trainee or junior faculty and hold an MD or MD/PhD 
Applicant must be actively employed in a hematology or hematology-related research environment 
The applicant must be an EHA member or EHA Guest at the time of application submission…

Read more